Eli Lilly & Co. vs. Omeros Corporation
Eli Lilly & Co. (LLY) comes out ahead, leading on 6 of 9 compared factors.
Size & Scale
| LLY | OMER | |
|---|---|---|
| Market Cap | $1.14 trillion | $1.33 billion |
| Revenue (TTM) | $79.67 billion | $38.42 million |
| Net Income (TTM) | $26.71 billion | $124.83 million |
LLY leads on 3 of 3 size & scale factors.
Valuation
| LLY | OMER | |
|---|---|---|
| P/E Ratio | 42.41 | 11.21 |
| Price / Book | 33.69 | -25.92 |
| Price / Sales | 14.33 | 34.65 |
OMER leads on 2 of 3 valuation factors.
Profitability
| LLY | OMER | |
|---|---|---|
| Net Margin | 33.53% | 324.88% |
| Return on Equity | 78.84% | -243.09% |
LLY and OMER split the profitability factors evenly.
Dividend
| LLY | OMER | |
|---|---|---|
| Dividend Yield | 0.55% | — |
| Payout Ratio | 23.23 | — |
LLY and OMER split the dividend factors evenly.
Risk & Sentiment
| LLY | OMER | |
|---|---|---|
| Short Interest | 1.29% | 9.61% |
LLY leads on 1 of 1 risk & sentiment factors.
Dig deeper: LLY overview, LLY financials, OMER overview, OMER financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.